Ciba Vision Voltaren
The claim that Voltaren (diclofenac ophthalmic solution) achieves "complete and normal corneal re-epithelialization equivalent to placebo" is misleading because Voltaren and other non-steroidal anti-inflammatory drugs delay healing, a July 16 FDA letter regarding Ciba Vision's April 15 advertisement in Ocular Surgery News says. FDA objects to the word "equivalent" because it would imply a similar period of recovery. A claim that Voltaren "significantly reduces oral narcotic use" also drew attention from FDA because there are no clinical data regarding the use of opiates with Voltaren
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth